Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas

Naofumi Asano, Hideyuki Takeshima, Satoshi Yamashita, Hironori Takamatsu, Naoko Hattori, Takashi Kubo, Akihiko Yoshida, Eisuke Kobayashi, Robert Nakayama, Morio Matsumoto, Masaya Nakamura, Hitoshi Ichikawa, Akira Kawai, Tadashi Kondo, Toshikazu Ushijima

Research output: Contribution to journalArticle

Abstract

Osteosarcoma (OS) patients with metastasis or recurrent tumors still suffer from poor prognosis. Studies have indicated the efficacy of DNA demethylation therapy for OS, but the underlying mechanism is still unclear. Here, we aimed to clarify the mechanism of how epigenetic therapy has therapeutic efficacy in OS. Treatment of four OS cell lines with a DNA demethylating agent, 5-aza-2′-deoxycytidine (5-aza-dC) treatment, markedly suppressed their growth, and in vivo efficacy was further confirmed using two OS xenografts. Genome-wide DNA methylation analysis showed that 10 of 28 primary OS had large numbers of methylated CpG islands while the remaining 18 OS did not, clustering together with normal tissue samples and Ewing sarcoma samples. Among the genes aberrantly methylated in primary OS, genes involved in skeletal system morphogenesis were present. Searching for methylation-silenced genes by expression microarray screening of two OS cell lines after 5-aza-dC treatment revealed that multiple tumor-suppressor and osteo/chondrogenesis-related genes were re-activated by 5-aza-dC treatment of OS cells. Simultaneous activation of multiple genes related to osteogenesis and cell proliferation, namely epigenetic reprogramming, was considered to underlie the efficacy of DNA demethylation therapy in OS.

Original languageEnglish
Article number20360
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Osteosarcoma
Epigenomics
Genetic Therapy
decitabine
Therapeutics
Genes
Chondrogenesis
Cell Line
CpG Islands
Ewing's Sarcoma
DNA Methylation
Morphogenesis
Heterografts
Osteogenesis
Methylation
Transcriptional Activation
Cluster Analysis
Neoplasms
Cell Proliferation
Genome

ASJC Scopus subject areas

  • General

Cite this

Asano, N., Takeshima, H., Yamashita, S., Takamatsu, H., Hattori, N., Kubo, T., ... Ushijima, T. (2019). Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas. Scientific reports, 9(1), [20360]. https://doi.org/10.1038/s41598-019-56883-0

Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas. / Asano, Naofumi; Takeshima, Hideyuki; Yamashita, Satoshi; Takamatsu, Hironori; Hattori, Naoko; Kubo, Takashi; Yoshida, Akihiko; Kobayashi, Eisuke; Nakayama, Robert; Matsumoto, Morio; Nakamura, Masaya; Ichikawa, Hitoshi; Kawai, Akira; Kondo, Tadashi; Ushijima, Toshikazu.

In: Scientific reports, Vol. 9, No. 1, 20360, 01.12.2019.

Research output: Contribution to journalArticle

Asano, N, Takeshima, H, Yamashita, S, Takamatsu, H, Hattori, N, Kubo, T, Yoshida, A, Kobayashi, E, Nakayama, R, Matsumoto, M, Nakamura, M, Ichikawa, H, Kawai, A, Kondo, T & Ushijima, T 2019, 'Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas', Scientific reports, vol. 9, no. 1, 20360. https://doi.org/10.1038/s41598-019-56883-0
Asano, Naofumi ; Takeshima, Hideyuki ; Yamashita, Satoshi ; Takamatsu, Hironori ; Hattori, Naoko ; Kubo, Takashi ; Yoshida, Akihiko ; Kobayashi, Eisuke ; Nakayama, Robert ; Matsumoto, Morio ; Nakamura, Masaya ; Ichikawa, Hitoshi ; Kawai, Akira ; Kondo, Tadashi ; Ushijima, Toshikazu. / Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{27af5f983e7f4adfaf711e1397e0a2e2,
title = "Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas",
abstract = "Osteosarcoma (OS) patients with metastasis or recurrent tumors still suffer from poor prognosis. Studies have indicated the efficacy of DNA demethylation therapy for OS, but the underlying mechanism is still unclear. Here, we aimed to clarify the mechanism of how epigenetic therapy has therapeutic efficacy in OS. Treatment of four OS cell lines with a DNA demethylating agent, 5-aza-2′-deoxycytidine (5-aza-dC) treatment, markedly suppressed their growth, and in vivo efficacy was further confirmed using two OS xenografts. Genome-wide DNA methylation analysis showed that 10 of 28 primary OS had large numbers of methylated CpG islands while the remaining 18 OS did not, clustering together with normal tissue samples and Ewing sarcoma samples. Among the genes aberrantly methylated in primary OS, genes involved in skeletal system morphogenesis were present. Searching for methylation-silenced genes by expression microarray screening of two OS cell lines after 5-aza-dC treatment revealed that multiple tumor-suppressor and osteo/chondrogenesis-related genes were re-activated by 5-aza-dC treatment of OS cells. Simultaneous activation of multiple genes related to osteogenesis and cell proliferation, namely epigenetic reprogramming, was considered to underlie the efficacy of DNA demethylation therapy in OS.",
author = "Naofumi Asano and Hideyuki Takeshima and Satoshi Yamashita and Hironori Takamatsu and Naoko Hattori and Takashi Kubo and Akihiko Yoshida and Eisuke Kobayashi and Robert Nakayama and Morio Matsumoto and Masaya Nakamura and Hitoshi Ichikawa and Akira Kawai and Tadashi Kondo and Toshikazu Ushijima",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-56883-0",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas

AU - Asano, Naofumi

AU - Takeshima, Hideyuki

AU - Yamashita, Satoshi

AU - Takamatsu, Hironori

AU - Hattori, Naoko

AU - Kubo, Takashi

AU - Yoshida, Akihiko

AU - Kobayashi, Eisuke

AU - Nakayama, Robert

AU - Matsumoto, Morio

AU - Nakamura, Masaya

AU - Ichikawa, Hitoshi

AU - Kawai, Akira

AU - Kondo, Tadashi

AU - Ushijima, Toshikazu

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Osteosarcoma (OS) patients with metastasis or recurrent tumors still suffer from poor prognosis. Studies have indicated the efficacy of DNA demethylation therapy for OS, but the underlying mechanism is still unclear. Here, we aimed to clarify the mechanism of how epigenetic therapy has therapeutic efficacy in OS. Treatment of four OS cell lines with a DNA demethylating agent, 5-aza-2′-deoxycytidine (5-aza-dC) treatment, markedly suppressed their growth, and in vivo efficacy was further confirmed using two OS xenografts. Genome-wide DNA methylation analysis showed that 10 of 28 primary OS had large numbers of methylated CpG islands while the remaining 18 OS did not, clustering together with normal tissue samples and Ewing sarcoma samples. Among the genes aberrantly methylated in primary OS, genes involved in skeletal system morphogenesis were present. Searching for methylation-silenced genes by expression microarray screening of two OS cell lines after 5-aza-dC treatment revealed that multiple tumor-suppressor and osteo/chondrogenesis-related genes were re-activated by 5-aza-dC treatment of OS cells. Simultaneous activation of multiple genes related to osteogenesis and cell proliferation, namely epigenetic reprogramming, was considered to underlie the efficacy of DNA demethylation therapy in OS.

AB - Osteosarcoma (OS) patients with metastasis or recurrent tumors still suffer from poor prognosis. Studies have indicated the efficacy of DNA demethylation therapy for OS, but the underlying mechanism is still unclear. Here, we aimed to clarify the mechanism of how epigenetic therapy has therapeutic efficacy in OS. Treatment of four OS cell lines with a DNA demethylating agent, 5-aza-2′-deoxycytidine (5-aza-dC) treatment, markedly suppressed their growth, and in vivo efficacy was further confirmed using two OS xenografts. Genome-wide DNA methylation analysis showed that 10 of 28 primary OS had large numbers of methylated CpG islands while the remaining 18 OS did not, clustering together with normal tissue samples and Ewing sarcoma samples. Among the genes aberrantly methylated in primary OS, genes involved in skeletal system morphogenesis were present. Searching for methylation-silenced genes by expression microarray screening of two OS cell lines after 5-aza-dC treatment revealed that multiple tumor-suppressor and osteo/chondrogenesis-related genes were re-activated by 5-aza-dC treatment of OS cells. Simultaneous activation of multiple genes related to osteogenesis and cell proliferation, namely epigenetic reprogramming, was considered to underlie the efficacy of DNA demethylation therapy in OS.

UR - http://www.scopus.com/inward/record.url?scp=85077209841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077209841&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-56883-0

DO - 10.1038/s41598-019-56883-0

M3 - Article

C2 - 31889115

AN - SCOPUS:85077209841

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 20360

ER -